Abstract
Background: The identification of mutations in the Isocitrate Dehydrogenase (IDH) gene in gliomas has considerable prognostic value, as patients with IDH-mutated tumors have a better overall survival than those without [1]. The IDH mutational status is therefore an important marker in the clinics and has the potential to open up for more personalized treatment approaches. It is usually assessed by immunohistochemistry or polymerase chain reaction (PCR) in tumor tissue obtained by surgical biopsies.
IDH-mutated tumor cells accumulate 2-hydroxyglutarate (2-HG) that is present in very low concentrations in normal tissue or in gliomas with wildtype IDH. It has recently been shown that 2-HG is detectable non-invasively by clinical Magnetic Resonance Spectroscopy (MRS) [2]. The aim of our study is to establish 2-HG MRS in patients suspected for cerebral gliomas on a clinical Magnetic Resonance (MR) system.
Material and Methods: We performed pre-surgical MRS in four grade 3 glioma patients. A standard MR protocol was combined with an optimized MRS sequence (single-voxel point-resolved spectroscopy)[3]. Metabolite quantification was performed using an unsuppressed water signal as reference. The overall acquisition duration was about 30 min. IDH mutational status in the tissue samples was analyzed by immunohistochemistry (3 cases) and PCR (1 case).
Results:
Two cases harbored IDH mutations, two had wildtype IDH, as assessed by immunohistochemistry or PCR. MRS detected IDH mutational status correctly in all four cases.
Conclusion: Our preliminary results confirm that IDH mutational status is detectable by non-invasive MRS.
1. Kloosterhof NK, Bralten LB, Dubbink HJ, French PJ, van den Bent MJ (2011); Lancet Oncol 12: 83-91.
2. Choi C, Ganji SK, DeBerardinis RJ, Hatanpaa KJ, Rakheja D, et al. (2012); Nat Med 18: 624-629.
3. Choi C, Ganji S, Hulsey K, Madan A, Kovacs Z, et al. (2013); NMR in Biomedicine 26: 1242-1250.
IDH-mutated tumor cells accumulate 2-hydroxyglutarate (2-HG) that is present in very low concentrations in normal tissue or in gliomas with wildtype IDH. It has recently been shown that 2-HG is detectable non-invasively by clinical Magnetic Resonance Spectroscopy (MRS) [2]. The aim of our study is to establish 2-HG MRS in patients suspected for cerebral gliomas on a clinical Magnetic Resonance (MR) system.
Material and Methods: We performed pre-surgical MRS in four grade 3 glioma patients. A standard MR protocol was combined with an optimized MRS sequence (single-voxel point-resolved spectroscopy)[3]. Metabolite quantification was performed using an unsuppressed water signal as reference. The overall acquisition duration was about 30 min. IDH mutational status in the tissue samples was analyzed by immunohistochemistry (3 cases) and PCR (1 case).
Results:
Two cases harbored IDH mutations, two had wildtype IDH, as assessed by immunohistochemistry or PCR. MRS detected IDH mutational status correctly in all four cases.
Conclusion: Our preliminary results confirm that IDH mutational status is detectable by non-invasive MRS.
1. Kloosterhof NK, Bralten LB, Dubbink HJ, French PJ, van den Bent MJ (2011); Lancet Oncol 12: 83-91.
2. Choi C, Ganji SK, DeBerardinis RJ, Hatanpaa KJ, Rakheja D, et al. (2012); Nat Med 18: 624-629.
3. Choi C, Ganji S, Hulsey K, Madan A, Kovacs Z, et al. (2013); NMR in Biomedicine 26: 1242-1250.
| Originalsprog | Engelsk |
|---|---|
| Publikationsdato | 13 jun. 2015 |
| Status | Udgivet - 13 jun. 2015 |
| Begivenhed | Neuroscience Symposium on Brain Tumors: XI Northern Lights - Hindsgavl, Middelfart, Odense, Danmark Varighed: 10 jun. 2015 → 13 jun. 2015 Konferencens nummer: XI |
Konference
| Konference | Neuroscience Symposium on Brain Tumors |
|---|---|
| Nummer | XI |
| Lokation | Hindsgavl, Middelfart |
| Land/Område | Danmark |
| By | Odense |
| Periode | 10/06/2015 → 13/06/2015 |